Pharmaceuticals and chemicals produce hemangiosarcomas (HS) in mice, often by nongenotoxic, proliferative mechanisms. A mode-of-action (MOA) for hemangiosarcoma was proposed based on information presented at an international workshop (Cohen et al., Hemangiosarcoma in rodents: Mode-of-action evaluation and human relevance. Toxicol. Sci. 111,[4][5][6][7][8][9][10][11][12][13][14][15][16][17][18]. Five key elements of the MOA were articulated and included hypoxia, macrophage activation, increased angiogenic growth factors, dysregulated angiogenesis/erythropoiesis, and endothial cell proliferation. The goal of the current study was to add to the weight-of-evidence for the proposed MOA by assessing these key elements with 3 different compounds of varying potency for HS induction: fenretinide (high), troglitazone (intermediate), and elmiron (low). Multiple endpoints, including hypoxia (hyproxyprobe, transcriptomics), endothelial cell (EC) proliferation, and clinical and anatomic pathology, were assessed after 2, 4, and 13-weeks of treatment in B6C3F1 mice. All 3 compounds demonstrated strong evidence for dysregulated erythropoiesis (decrease in RBC and a failure to increase reticulocytes) and macrophage activation (4-to 11-fold increases); this pattern of hematological changes in mice might serve as an early biomarker to evaluate EC proliferation in suspected target organs for potential HS formation. Fenretinide demonstrated all 5 key elements, while troglitazone demonstrated 4 and elmiron demonstrated 3. Transcriptomics provided support for the 5 elements of the MOA, but was not any more sensitive than hypoxyprobe immunohistochemistry for detecting hypoxia. The overall transcriptional evidence for the key elements of the proposed MOA was also consistent with the potency of HS induction. These data, coupled with the previous work with 2-butoxyethanol and pregablin, increase the weight-ofevidence for the proposed MOA for HS formation.
rodents (ie, mouse or rat). Both examples are genotoxic carcinogens (vinyl halides and Thorotrast), and produce primarily liver hemangiosarcoma (Boivin-Angè le et al., 2000; Lipshutz et al., 2002) . In contrast, commercial pharmaceutical products and chemicals that produce HS solely in mice, appear to act by nongenotoxic, proliferative mechanisms . The pharmacology of these compounds is diverse and includes calcium channel blockers, antipsychotics, phosphodiesterase-5 inhibitors, dipeptidyl peptidase-4 inhibitors, antiarrhythmics, gonadotropin receptor antagonists, antisense compounds, nitric oxide releasers, hemolytic compounds, and vascular endothelial growth factor (VEGF) inducers .
In 2009, a mode-of-action (MOA) for hemangiosarcoma was proposed based on information presented at an international workshop . The emerging data suggested that these different compounds share a common point of intersection and interaction with growth regulatory pathways ; specifically, agents that induce hemangiosarcoma appear to have initiating events that lead to local tissue hypoxia and macrophage activation. These 2 changes increase angiogenic growth factors. This process was analogous to physiologic angiogenesis, but it was hypothesized that agents that induce hemangiosarcoma produce dysregulated angiogenesis and/or erythropoiesis. Dysregulated angiogenesis embodies the concept that the hypoxia cannot be compensated by new blood vessel formation or that the stimulated ECs do not form functional blood vessels such as in the case of the blind vessels commonly seen in hemangiosarcoma in the liver of mice. Dysregulated erythropoiesis in bone marrow and spleen accompanied by an increase in macrophages embodies the concept that there is a failure to produce functional erythrocytes in these organs contributing to sustained tissue hypoxia.
The components of the MOA for hemangiosarcoma proposed above have been extensively studied with 2-butoxyethanol (2-BE) and pregabalin, both of which induce hemangiosarcoma in mice but not rats. 2-BE induces hemangiosarcoma primarily in the liver (Nyska et al., 2004) and pregabalin induces hemagiosarcoma in bone marrow, liver, and spleen (Pegg et al., 2012) . Both compounds induce local tissue hypoxia, but by different mechanisms; 2-BE via its induction of hemolysis (Laifenfeld et al., 2010; Nyska et al., 2004) and pregabalin presumably via its effects on systemic pH mediated by the increase in bicarbonate (Criswell et al., 2012a,b) . Pregabalin (Criswell et al., 2012a) , and 2-BE (Corthals et al., 2006; Klaunig and Kamendulis, 2005; Park et al., 2002a,b; Siesky et al., 2002) have also been shown to activate macrophages, which may play a contributing role in this MOA by increasing angiogenic cytokines such as interlukin (IL)-6 and increasing reactive oxygen species, which can also contribute to deoxynucleic acid (DNA) damage of ECs (Corthals et al., 2006; Klaunig and Kamendulis, 2005; Park et al., 2002a,b; Siesky et al., 2002) . Hence, divergent initiating events lead to a convergence around hypoxia and macrophage activation.
Understanding the pathogenesis of hemangiosarcoma using immunohistochemical staining of cell markers was undertaken in order to provide insight as to human relevance of these tumors Liu et al., 2013) . For instance, ECs from hemangiosarcoma may either involve transformation of differentiated ECs in the target organ or recruitment of transformed bone marrow-derived stem cells or endothelial progentior cells (EPCs) (Lamerato-Kozicki et al., 2006) . In mice, both spontaneous and chemically-induced hemangiomas and HS appear to be derived from an EPC origin based on their expression of CD34, VEGFR2, and CD31, but not factor VIII antigens . In humans, hemangiomas appear to be derived from late EPCs or differentiated ECs while HS are derived from bone marrow-derived hematopoietic stem cells or early EPCs based on their expression of CD117, CD34, and CD45 antigens (Liu et al., 2013) . Unlike in mice, hemangiomas and HS in humans appear to have distinct pathogenesis supporting the conclusion that human hemangiomas do not progress to HS. Hence, the cell marker analysis did not provide definitive evidence to conclude whether this tumor type is revelant to humans Liu et al., 2013) . There are however several lines of evidence that suggest why the mouse is more susceptible than rats or humans to the induction of hemangiosarcoma by nongenotoxic agents (Reviewed in Cohen et al., 2009 ): (1) spontaneous incidence is higher in mice than in rats or humans; (2) spontaneous EC proliferation rates correlate with the spontaneous incidence across species; (3) agents such as troglitazone increase EC proliferation in cells isolated from mice but not humans; (4) human disease states (eg, Chuvask polycythemia) suggest humans are more resistant than mice for development of hemangiosarcoma; and (5) mice have lower antioxidant levels (eg, vitamine E) than rats and humans which may contribute to their enhanced susceptibility to developing HS (Corthals et al., 2006; Criswell et al., 2012a) .
To further test components of this MOA framework, 3 compounds of divergent potency and action were selected to increase the weight-of-evidence; namely, elmiron (sodium pentosan polysulfate, bladder pain analgesic), troglitazone (peroxisome proliferator-activated receptor gamma [PPARc] agonist), and fenretinide (retinoic acid receptor [RAR] agonist). These compounds possessed low to high potency for HS induction in mice, but not rats, respectively (Table 1) . Troglitazone and fenretinide but not elmiron produced hemangiosarcoma in multiple organs with multiplicity within an animal (Abdo et al., 2003; Goldenthal and Crowell, 2005; Crowell and Glodenthal, 2006; Herman et al., 2002) . Elmiron has the lowest potency producing hemangiosarcoma only in the liver without tumor multiplicity. Troglitazone has intermediate potency producing hemangiosarcoma in the bone marrow, brown adipose/subcutis fat, liver, and spleen. Fenretinide is the most potent agent producing hemangiosarcoma within 1 year of treatment and an almost 100% incidence of hemangiosarcoma by 2 years. In males, fenretinide produces hemangiosarcoma in the hematolymphoreticular system (ie, bone marrow, liver, lymph node, spleen), epididymis, epididymal white fat pads, and subcutis fat. Based on the tumor responses with the 3 compounds, we chose male mice to study a time-course for these initiating events since they appeared to have a higher response than females. A battery of endpoints was assessed after 2, 4, and 13-weeks of treatment including hypoxia (hypoxyprobe, transcriptomics), EC proliferation, and clinical and anatomic pathology. In addition, the methods applied in studying 2-BE and pregabalin were assessed for their utility when applied to weaker agents such as troglitazone and elmiron.
MATERIALS AND METHODS

Animals
Male B6C3F1 mice were obtained from Charles River Laboratories (Kingston, New York). All mice used in this study were housed in a facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International and used in accordance with an approved animal care and use protocol, the Institute for Laboratory Animal Research Guide for the Care and Use of Laboratory Animals (National Research Council, 1996) and all applicable regulations.
Study Design and Dose Rationale
This work was performed as 3 separate studies: 10GR145 (fenretinide), 10GR202 (troglitazone), and 10GR221 (elmiron). Prior to the conduct of the 13-week studies, one-month pilot studies were conducted with each compound using the same dose levels as in this report with the following endpoints: body weight, food consumption, clinical pathology, organ weights (liver, BAT, WAT) and histopathology (data not reported). The pilot studies demonstrated no adverse findings as well as confirming adequate target organ responses (hypoxia, cell proliferation, and transcriptomics). Fenretinide (N-[4-Hydroxyphenyl] retinamide) is a RAR agonist. In carcinogenicity studies with B6C3F1 mice, it has been shown to induce HS in subcutis and abdominal soft tissue in mice with an incidence approaching 100% after 2 years at 50 and 250 mg/kg (Table 1, Goldenthal and Crowell, 2005) . Mechanistically, fenretinide is thought to bind RAR in vitro to regulate cell growth and angiogenesis possibly through RAR independent pathways. It has also been shown to induce EC apoptosis via increased production of ceramide via unknown mechanisms ). We chose a dose of 500 mg/kg fenretinide to investigate the effects on EC proliferation and hypoxia status in male B6C3F1 mice when administered via diet for up to 13 weeks based on the 1-month pilot study showing no adverse findings. In the 1-month pilot study, the 500 mg/kg fenretinide dose resulted in blood levels of 2846 and 2188 ng/ml on study days 15 and 29, respectively.
Troglitazone is a member of the thiazolidinediones. It is a known PPAR gamma agonist that produces an increased incidence of hemangiosarcoma in B6C3F1 mice at 400 and 800 mg/ kg (Table 1, Herman et al., 2002) . It has been shown to increase EC proliferation in numerous tissues, including heart, brown fat, and white fat (Breider et al., 1999; Kakiuchi-Kiyota et al., 2009) . We chose a dose of 1200 mg/kg to investigate the effects of troglitazone on EC proliferation and hypoxia status in male B6C3F1 mice when administered orally for up to 13 weeks based on the pilot study described above as well as work by Breider et al., 1999 that also used 1200 mg/kg. In a previous 4-week study using B6C3F1 mice, the AUC values were 5.3 and 31 mg . h/ml at 1000 and 5000 mg/kg and confirmed that no significant toxicity was observed (Pegg et al., 2012) . In humans, an 800 mg troglitazone dose results in a AUC value of 5.6 mg . h/ml and a C max value of 3.24 mg/ml (data from PharmaPendium, www.phar mapendium.com) . Elmiron (xylan hydrogen polysulfate, sodium pentosan polysulfate) is a highly sulfated, semi-synthetic pentose polysaccharide that is manufactured from raw materials of beechwood shavings (Anderson and Perry, 2006) . It has similar properties to heparin and exhibits antilipidemic and marked anticoagulant activities, fibrinolytic, antiflogistic, mild antihypertensive effects, and inhibition of vascular smooth muscle cell proliferation (Abdo et al., 2003) . In the USA, elmiron is used to relieve pain from interstitial cystitis. The MOA for treating this disease is due to elmiron's ability to preferentially localize in the lining of the pelvis, ureters, and bladder of the urinary tract (Nyska et al., 2002) . Elmiron has also been shown to increase hemangiosarcoma in the liver of B6C3F1 mice treated with 168 and 504 mg/kg (Table 1, Abdo et al., 2003) . We chose a dose of 1000 mg/kg to investigate the effects of elmiron on EC proliferation and hypoxia status in male B6C3F1 mice when administered orally for up to 13 weeks based on the work by Nyska et al. (2002) that used this dose without significant toxicity for 13 weeks and confirmed by our 1-month pilot study. In humans, a 400 mg elmiron dose results in a AUC value of 1178 ng . h/ml and a C max value of 54 ng/ml (data from PharmaPendium); toxicokinetic data from mice is unavailable For all 3 compounds, a time course study of 2 (transcriptomics only), 15, 29, and 92 days was designed to determine when proliferative and/or hypoxic changes occur in the tissues where HS develop for the 3 compounds. A roughly 2-fold dose from the carcinogenicity high doses was used to maximize the potential to measure these changes. Since the 1-month pilot studies did not result in any significant findings (body weight, food consumption, clinical signs, or clinical pathology) that were considered to be at a maximum tolerated dose. We chose a higher doses than the carcinogenicity studies to maximize our ability to detect the measured changes in these studies consistent with concentration Â time relationship (ie, No observable effect levels generally decrease as one increases the duration of exposure).
Hematology
Blood samples containing EDTA as an anticoagulant were collected by cardiac puncture from 10 untreated control or 10 mice receiving fenretinide, troglitazone, or elmiron on days 15, 29, Reagan et al. (2011) and Criswell et al. (2014) : (1) preparation of cytocentrifuge slides for microscopic determination of bone marrow differentials, (2) enumeration of total myeloid and total erythroid numbers, (3) enumeration of bone marrow macrophages, and (4) calculation of myeloid to erythroid ratio (M:E). A total of 500 cells were counted using a microscope to calculate myeloid and erythroid cell numbers. The opposing femur, spleen and liver were harvested from each animal for histopathology.
Histology
Mice were were not fasted prior to necropsy. Animals and groups were randomized using a computer program prior to necropsy which was initiated at approximately 8 AM for each time point. Mice were euthanized by 1 of 2 procedures: Isoflurane gas anesthesia followed by exsanguination for EC proliferation endpoints, or by cervical dislocation under ketamine/acepromazine anesthesia (75/2.5 mg/kg, respectively) for hypoxia endpoints. All procedures used in these studies were reviewed and approved by the Institutional Animal Care and Use Committee. At necropsy, the following tissues were collected, weighed, and fixed in 10% neutral buffered formalin: liver, spleen, brown scapular adipose, and white epididymal adipose. Additionally, femurs were collected, fixed in 10% neutral buffered formalin, and then decalcified by immersion in ImmunoCal (Decal Corporation, Tallman, New York). All tissues were processed to paraffin blocks according to routine histological procedures. The slides were reviewed by the pathologist in an unblinded manner.
Hematoxylin and Eosin Staining
Five micron sections were cut and mounted on glass slides. All Hematoxylin and Eosin staining was completed using the Ventana Symphony (Ventana Medical Systems, Tucson, Arizona) slide stainer using the system's reagents according to manufacturer's directions.
Immunohistochemistry
Five micron sections were cut and mounted onto charged slides and used for the following immunohistochemical procedures:
Hypoxyprobe immunohistochemistry. To expose the antigen recognized by Hypoxyprobe (HPI, Burlington, Massachusetts), sections were pretreated with a Citrate Buffer (Chemicon, Temucula, California) using a Decloaking Chamber from Biocare Medical, Walnut Grove, California. All Hypoxyprobe immunohistochemical detections were performed on an automated Dako Autostainer (Dako, Carpinteria, California). Endogenous peroxidase was blocked by incubation in 3.0% hydrogen peroxide (aq) for 10 min. Dako Protein block was applied for 20 min to block nonspecific reactions. The Hypoxyprobe reagent was run at a dilution of 1/500 for 60 min at room temperature, and detected by using Dako Envisionþ Rabbit HRP Polymer for 30 min and visualized by using Dako Liquid diaminobenzidine (DABþ). All slides were then counterstained for nuclear detail using Mayer's hematoxylin, dehydrated, cleared, and mounted with a permanent mounting media. Negative controls for the study included a rabbit isotype control antibody (Vector, Burlingame, California) incubated for 60 min using the same detection system described above. Additionally, tissues from mice exposed to hypoxia, as well as those collected from mice maintained in a normal oxygen environment, were run in parallel as further positive and negative tissue controls for detecting local tissue hypoxia (Laifenfeld et al., 2010) .
EC proliferation immunohistochemistry. To expose antigenic sites, sections were pre-treated with Borg Retrieval Solution (Biocare Medical, Walnut Grove, California) using a Decloaking Chamber from Biocare Medical. All CD31 þ bromodeoxyuridine (BrdU) immunohistochemical detections were performed on an automated Dako Autostainer. Endogenous peroxidase was blocked by incubation in 3.0% hydrogen peroxide (aq) for 10 min. Dako Protein block was applied for 20 min to block nonspecific reactions. Goat antiCD31 (Santa Cruz Biotechnology, Santa Cruz, California) was applied at a dilution of 1/1000 for 60 min at room temperature, and detected by using a peroxidase conjugated donkey anti goat IgG secondary antibody at 1/250 for 45 min (Jackson Immunoresearch, West Grove, Pennysyvania), followed by a 10 min incubation in a 1/50 dilution of Cy5-TSA (Perkin Elmer, Waltham, Massachusetts). Next a sheep antiBrdU antibody (Novus Biologicals, Littleton, Colorado) was applied at a dilution of 1/300 for 60 min at room temperature, and detected by using an Alexa fluor 488 donkey antisheep IgG secondary antibody run at 1/300 for 45 min (Invitrogen, Carlsbad, CA). All slides were then counterstained with 4 0 ,6-diamidino-2-phenylindole (DAPI) (Invitrogen, Carlsbad, California) for 10 min, washed in PBS followed by distilled water and coverslipped with Prolong Gold Antifade mounting media (Invitrogen, Carlsbad, California). Negative controls included goat and sheep isotype control antibodies run at the same concentrations as CD31 and BrdU, respectively (Jackson Immunoresearch).
Immunohistochemistry for oxidative stress and mitochondria injury.
To expose antigenic sites, sections were pre-treated with Borg Retrieval Solution or EDTA (Invitrogen, Carlsbad, California) for mnSOD and VDAC-1 (porin), respectively, using a Decloaking Chamber. All mnSOD and porin immunohistochemical detections were performed on an automated Dako Autostainer. Endogenous Peroxidase was blocked by incubation with 3.0% hydrogen peroxide (aq) for 10 min, followed by 20-min incubation with Dako Protein Block to block non-specific binding. Rabbit anti-mnSOD (Thermo Scientific, Kalamazoo, Michigan) and Rabbit anti-porin (Epitomics, Burlingame, California) were applied at dilutions of 1/100 and 1/750 for 1 h at room temperature. Both antibodies were detected by using Dako Envisionþ Rabbit HRP Polymer for 30 min and visualized by using Dako Liquid DABþ. All slides were then counterstained for nuclear detail using Mayer's hematoxylin, dehydrated, cleared, and mounted with a permanent mounting media. Negative controls for the study included a rabbit isotype control antibody (Vector, Burlingame, California) incubated for 60 min using the same detection system described earlier.
Cell Proliferation
For the elmiron, fenretinide, and troglitazone studies, paraffin sections were cut from the liver, subscapular brown fat, and epididymal white fat. Tissues were stained as described earlier.
Proliferating ECs were measured using the iCyte LSC (Compucyte, Westwood, Massachusetts). The approach was as conducted as previously described (Criswell et al., 2012b) . A mosaic scan of the entire tissue section was created at 20Â objective and 20 mm step size to create a low resolution tissue map. From this map ten 760 Â 568 mm scan areas were randomly distributed within the tissue, which were then subjected to highresolution image capture using a 40Â objective and 0.25 mm step size. The total area sampled at high resolution for each liver tissue section was 4.32 mm 2 . A 405 nm laser was used for DAPI excitation, while Alexa Fluor 488 and Cy5 were excited with 488 and 633 nm lasers, respectively. Contour thresholds were automatically optimized by the software for each fluorophore based on intensity. Similar to flow cytometry, scattergrams of contoured nuclei (DAPI), proliferating nuclei (BrdUþ), and CD31 positive areas (CD31þ) were used to identify density and location of these events within the liver section. Nuclei within CD31þ regions were characterized as EC nuclei and those nuclei positive for BrdU labeling were measured as proliferating cells. Co-localized ECs and proliferating cells were characterized as proliferating ECs. From these associations the following measurements are reported: TNC (TNC count), relative number of CD31þ (percent ECs), absolute number CD31þ (EC count), relative number of BrdUþ (percent proliferating cells), absolute number of BrdUþ (proliferating cell count), relative number of CD31þ BrdUþ (percent of proliferating ECs) and absolute number of CD31þ BrdUþ (proliferating EC count).
Cell counts from each animal were obtained from the same total tissue area of 4.32 mm 2 as previously described in Criswell et al. (2012b) . Briefly, proliferating cells were identified by nuclear colocalization of BrdU and DAPI signal, while ECs were identified as those DAPI events within CD31þ regions. Those CD31þ nuclei that were also BrdUþ were categorized as proliferating ECs. Raw counts of these events were obtained from the LSC and were validated by viewing images of the events falling within the above groups. When necessary, data points representing staining artifacts were removed through careful deselection of events using strict intensity, shape and size parameters. Raw data was exported into a Microsoft Excel spreadsheet where percent values, means and standard deviations were tabulated. Statistical analyses were performed separately for each tissue (liver, brown adipose, and white adipose), day, and endpoint. The measurements for tissue, day, and endpoint were transformed to normal scores, and the transformed data were then analyzed using a 2 sample t-test. Results were reported at the 0.05 or 0.01 levels of significance.
Assessment of Transcriptomic Effects
Ribonucleic acid (RNA) isolation, transcriptional profiling, and quantification of expression changes were conducted as described previously in Laifenfeld et al. (2010) . Briefly, total RNA was extracted from the liver, subscapular brown fat, and epididymal white fat and complimentary DNA (cDNA) synthesized. complimentary RNA was transcribed from cDNA using the GeneChip One-Cycle Labeling Kit from Affymetrix (Affymetrix, Santa Clara, CA), hybridized to Mouse M430 v2.0 GeneChip microarrays, and analyzed using the "affy" and "limma" packages of the Bioconductor suite of microarray analysis tools available for the R statistical environment (Gentleman, 2005; Gentleman et al., 2004; Irizarry et al., 2003) . An analysis of variance model was used for the statistical analysis. Probe sets were considered to have changed qualitatively in a specific comparison if an false discovery rate (FDR)-adjusted p-value of .2 was obtained, their average expression intensity was above 100 in either treatment group, and they had an absolute fold change >1.3. Genes represented by multiple probe sets were considered to have changed if at least 1 probe set was observed to change. Gene expression changes that met these criteria were called "statistically significant differentially expressed genes (DEGs)" and have the directional qualities of "up" or "down" (ie, they can be upregulated or downregulated in response to treatment).
Causal Reasoning and Text-Mining Analysis
The Causal Reasoning Engine (CRE) (Chindelevitch et al., 2012 ) is a computational platform to identify hypothetical upstream controllers from DEGs observed in a specific experiment. The method relies on a large knowledgebase of biological concepts and entities and their causal relationships. Relationships are manually curated from peer-reviewed scientific literature and public and proprietary databases. Inferred upstream controllers are called "hypotheses" as they are statistically significant potential explanations of the gene expression changes. For this study, hypotheses related to hypoxia (response to hypoxia, and the transcriptional activities of hypoxia-inducible factor 1 alpha (Hif1a) and endothelial PAS domain protein 1 [Epas1]), inflammation, and cell proliferation were primarily evaluated. These hypotheses were defined in previous work with reference compounds/treatments (Laifenfeld et al., 2010) . CRE provides enrichment p-values to assess deviations from a null model of random assignment of DEGs to the knowledgebase. We considered p-values < 1e-4 as significant and inspected hypotheses with p-value < .05 in cases of biological interest. In addition, we conducted a literature search for molecular entities related to "hemangiosarcoma" using the Pfizer-internal LitMS textmining platform. LitMS regularly scans all available PubMed abstracts for co-occurrence of relevant terms, ie, in our use case for synonyms of "hemangiosarcoma" and all known gene and protein names. Interally, LitMS uses the Apache Lucene information retrieval library to perform dictionary look-ups and extract contextual and positional features from the text, which are then passed to one of several scoring algorithms to assess relevance to specific topics of interest (Bichko et al., 2012) . Finally, we utilized Medical Subject Heading (MeSH) clouds for interpreting CRE results as described in O'Connor et al. (2014) . Briefly, each relationship in the knowledgebase is linked to 1 or more scientific article. If articles have been manually annotated with MeSH terms in the PubMed database, it becomes possible to assess MeSH terms (such as "leucocytes", "DNA damage", or "inflammation") for their enrichment in relationships supporting a specific hypothesis.
RESULTS
Organ Weights
Body weight changes were only observed on day 29; fenretinidetreated mice had a slight decrease in body weight (4.58%) whereas troglitazone-treated mice had a slight increase in body weight (1.07-fold) ( Table 2 ). Both weight changes were transient and returned to normal values by day 92. Elmiron did not significantly affect body weight. Increases in absolute and relative liver weight were observed for all 3 compounds variably across the time points. Fenretinide-treated mice had statistically significant increased liver weight for all time points (1.16-to 1.37-fold absolute, 1.2-to 1.39-fold relative), whereas troglitazonetreated mice had increased liver weight at day 15 (1.11-fold absolute, 1.0-fold relative) and day 29 (1.11-fold absolute), but there was also trend for increased liver weight at day 92 (1.04 fold absolute). Elmiron-treated mice had statistically significant increased liver weight at day 15 (1.11-fold absolute, 1.06-fold relative) and day 92 (1.22-fold absolute, 1.22-fold relative) with a trend for increased liver weight at day 29 (1.07-fold absolute). Increases in absolute and relative spleen weight were observed in fenretinide and elmiron-treated mice. Fenretinide-treated mice had statistically significant increased spleen weight at all time points (1.12-to 1.39-fold absolute, 1.14-to 1.42-fold relative), whereas elmiron-treated mice had increased spleen only at day 92 (1.16-fold absolute, 1.15-fold relatve) with a trend for increased spleen weight at day 29 (1.13 fold absolute). In contrast, troglitazone-treated mice had statistically significant decreased spleen weight at day 92 (19.74% absolute, 25.2% relative). Statistically significant decreases in absolute and relative white adipose tissue (WAT) weight were observed for fenretinide-treated mice at all time points (60.26%-74.86% absolute, 59.54%-73.99% relative), but decreases in brown adipose tissue (BAT) weight were observed on day 15 (16.74% absolute, 14.59% relative) and day 29 (21.9% absolute) with a trend for decreased BAT weight at day 92 (12.51% absolute). Troglitazone and elmiron-treated mice did not have biologically significant organ weight changes in white or BAT.
Hematology and Bone Marrow-Effects of Fenretinide
Fenretinide induced multiple effects on red blood cell parameters that were present within 15 days of dosing and increased in intensity during the 92 days of the study (Table 3 ). The RBC in fenretinide-treated mice were 5.7%, 9.5%, and 9.8% lower than controls on days 15, 29, and 92, respectively. Decreases in hemoglobin concentrations were even more pronounced reaching 17% lower than controls by day 92. Reticulocyte counts were 17% lower in treated mice compared with controls on day 15 and failed to show a significant increase on either days 29 or 92 despite decreases in RBC and hemoglobin. RDW showed a progressive increase over time, indicating increased variability in red cell size. Fenretinide treatment also induced effects on multiple white blood cell and platelet parameters that were present by 15 days of dosing and persisted through the 3 months of the study (Table 4) . Fenretinide produced 2-to 3-fold increases in WBC with elevations in peripheral blood neutrophils, lymphocytes, and monocytes at all 3 time points. LUCs are a unique cell type identified only with the Advia hematology analyzer. LUC indicate cells that are peroxidase negative, but larger than normal lymphocytes. Increases in LUC are associated with presence of blasts, immature cells, or cells that possess both monocyte and lymphocyte features. Fenretinide induced approximately 4-, 5-, and 6-fold increases in LUC on days 15, 29, and 92. Platelet counts were significantly decreased from 16% to 39% over the 3 assessment days.
Fenretinide decreased bone marrow TNC count by 16% on day 29 and 31% on day 92 (Table 5 ). The M:E ratio was increased at all 3 time points, due to a decrease in total erythroid cells. Decreases in total erythroid cells were 23% lower than untreated controls on day 15 and reached 55% lower than controls by day 92. Bone marrow macrophage number were increased by approximately 6-fold on days 15 and 29 and nearly 11-fold by day 92 following fenretinide treatment.
Hematology and Bone Marrow-Effects of Troglitazone
Troglitazone produced small, but statistically different, decreases in RBC and hemoglobin that remained <4% compared with the controls, but was not different from controls by day 92. Reticulocyte counts were decreased by 14% and 29% in troglitazone-treated mice on days 29 and 92, respectively (Table  3) . Troglitazone decreased WBC by 50% by day 92, largely due to decreases in lymphocytes (Table 4) . Troglitazone produced no effects on LUC or platelet count (Table 4) . Troglitazone produced statistically different decreases on bone marrow M:E on days 29 and 92. However, the effects were small (approximately 25%). The only persistent change in bone marrow was an increase in macrophage number of 4-, 7-, and 4-fold with troglitazone treatment on days 15, 29, and 92, respectively (Table 5) Hematology and Bone Marrow-Effects of Elmiron Elmiron had very limited effects on red blood cell parameters with the most notable change being a decrease in reticulocyte counts of 16%, 9%, and 21% on days 15, 29, and 92, respectively (Table 3) . Neutrophils, monocytes and platelet counts showed minimal changes in elmiron-treated mice, but they were not persistent over time. Elmiron did produce a significant 3-fold increase in LUC by day 92 (Table 4) .
The most persistent changes induced by elmiron were decreases on bone marrow M:E produced by increases in total erythroid cells. Total macrophage numbers in bone marrow were also increased by approximately 4-, 7-, and 8-fold on days 15, 29, and 92, respectively (Table 5) .
Histopathology
Hepatocyte hypertrophy was observed at all time points for fenretinide and troglitazone-treated mice which would correlate with increased organ weight findings (Table 6 ). The hepatocyte hypertrophy was primarily centrilobular for both compounds. The severity of the hepatocyte hypertrophy increase over time in fenretinide-treated mice and single cell hepatocyte necrosis was also observed at days 29 and 92. Elmiron-treated mice had hepatocyte vacuolation and mixed cell infiltrates observed at day 92; the vacuolation may have contributed to the increased organ weight finding at that time point. Extramedullary hematopoiesis (EMH) was observed in the spleen of fenretinide and elmiron-treated mice at days 29 and 92 which correlates with increased spleen weight. The background incidence of EMH in B6C3F1 mice in 3-month studies is not routinely collected by our laboratory or Contract Research Organizations, but has been reported to be 17.6% (6.1-28 range) in males and 28.8% (12-52 range) in females from NTP feeding studies (Maronpot et al., 1999) . Elmiron-treated mice also had hyperplasia of the splenic marginal zone and accumulation of foamy macrophages in the splenic sinusoids at day 92 which may have also contributed to the increased spleen weight at that time point. In contrast, lymphoid depletion with germinal center apoptosis was observed at day 92 in troglitazone-treated mice which correlate with the decreased spleen weight at that time point. Decreased cytoplasmic fat content, as well as transdifferentiation into a brown adipose phenotype was observed in the WAT of fenretinidetreated mice at all time points and may have contributed to the decreased weight seen at those time points. Decreased cytoplasmic fat content in WAT was also observed in elmirontreated mice at day 29 which was transient and not present at 
Hypoxyprobe Immunohistochemistry
Local tissue hypoxia was observed in subsets of tissues from all 3 compounds at varying time points (Table 7 , Figure 1 ). Cytoplasmic immunoreactivity was observed in the centrilobular regions of the liver and the red pulp areas of the spleen from all treatments, while the staining was more diffuse in BAT, WAT, and bone marrow. Specifically, increases in tissue hypoxia were seen at day 29 of fenretinide treatment in liver, spleen, BAT, and WAT. The increase in the spleen was retained out to day 92, while an initial decrease in tissue hypoxia was seen in WAT at day 15. Troglitazone treatment showed early increases in tissue hypoxia in the liver at day 15 that was resolved by day 29 and increased again at day 92. WAT hypoxia was also seen at day 29. Little change was seen with elmiron treatment, as only small increases in tissue hypoxia were observed at day 92 in the spleen, and days 15 and 92 in the bone marrow. Generally, there was a trend of increased local tissue hypoxia in most tissues with fenretinide treatment by day 29. However, with troglitazone and elmiron, increases or decreases in tissue hypoxia were variable being seen in all tissues at different time points.
Cell Proliferation Analysis
Administration of fenretinide to male B6C3F1 mice for 15 and 29 days resulted in expected changes in overall proliferation and EC proliferation in BAT and WAT (Table 8) . Specifically, no changes were observed within the subscapular BAT of animal treated with fenretinide at either time point. However, statistically significant increases in absolute and relative total proliferating and proliferating ECs were observed at 92 days. For WAT, a statistically significant increase in absolute and relative proliferation was present at all time points. Fenretinide effects on the liver were more complex and results of total cell number, EC number, total proliferating cells, and proliferating EC values are reported in Table 8 and  Supplementary Table 1 . Following 15 days of fenretinide treatment, significant increases in relative ECs, absolute and relative proliferating cells, as well as absolute and relative proliferating ECs were observed compared with untreated controls. However, no significant differences were observed in absolute and relative proliferating ECs between livers of treated versus untreated animals at day 29. Interestingly, this change was not observed at day 92 and statistically significant changes in total nuclear count as well as absolute and relative proliferating cells and proliferating ECs were again seen.
Administration of troglitazone to male mice resulted in no proliferative effect changes of epididymal WAT as was reported in (Breider et al., 1999) . In contrast, statistically significant increases in absolute and relative total proliferating cells and proliferating ECs were observed in BAT at days 15 and 92 of troglitazone administration (Table 8 and Supplementary Table  2 ). Additionally, absolute and relative total ECs were significantly decreased at 92 days but not at any other time points. No changes were observed at 29 days for any of the end points in BAT.
Measurements of total cell number, EC number, total proliferating cells and proliferating ECs were also made on the livers of study animals, which are reported in Table 8 . Following 15 days of troglitazone treatment significant increases in absolute ECs, absolute proliferating cells, and absolute and relative proliferating ECs were observed compared with untreated controls. However, no significant changes were observed in livers of animals receiving troglitazone at days 29 and 92, when compared with animals receiving vehicle only.
Administration of elmiron to male mice for all 3 time points resulted in no changes in overall proliferation and EC proliferation in BAT (Table 8 and Supplementary Table 3 ). However, statistically significant increases were found in relative EC numbers at day 29 and in total nuclei count as well as absolute numbers of ECs at 92 days. No changes were observed within the WAT of animals treated with Elmiron at all 3 time points.
Effects of Elmiron administration in liver were complex (see Supplmentary Table 3 ) Following 15 days of Elmiron treatment, no significant changes in the measured endpoints between treated and untreated controls. However, statistically significant decreases were observed at day 29 in total nuclei count, as well as relative and absolute EC numbers. At day 92, this change was no longer observed, but statistically significant increases were present in relative and absolute proliferating cells as well as relative and absolute proliferating ECs.
Porin and mnSOD Immunohistochemistry
For all 3 compounds, liver tissues from day 92 were evaluated for porin (mitochondrial injury marker) and mnSOD (oxidative stress marker) immunostaining. Both mitochondrial markers show increased immunostaining in the treated mice compared with their concurrent controls. Porin immunostaining (Figure 2 ) demonstrated more robust staining difference than mnSOD immunostaining (data not shown) and fenretinide-treated mice had greater porin immunostaining intensity than the troglitazone-or elmiron-treated mice.
Transcriptomics
Tissue samples from the days 15 to 29 necropsies were profiled on Affymetrix GeneChips to measure global changes in gene expression. Samples from day 92 were not used because we wanted to profile the earlier molecular events involved in Up arrow indicates direction of change in treated group in relation to vehicle control group (fold change).
Down arrow indicates direction of change in treated group in relation to vehicle group (percent change from control).
NC, no Change; NA, not available. *Significant difference from control at the 1% level (2-sided t-test for independent samples using a pooled estimate of the variance performed on the logged data). **Significant difference from control at the 5% level (2-sided t-test for independent samples using a pooled estimate of the variance performed on the logged data).
***Significant difference from control at the 10% level (2-sided t-test for independent samples using a pooled estimate of the variance performed on the logged data).
initiating HS. A potential limitation of the transcriptomic analysis was that whole tissue was used for the isolation of the RNA rather than ECs isolated from the tissue. However, whole tissue analysis was conducted since hepatocytes, Kupffer cells, and infiltrating leukocytes will all affect sinusoidal ECs which is why whole tissue analysis was ultimately selected. DEGs were evaluated using the CRE as described in "Materials and Methods" Section. Hypotheses related to elements of the generalized MOA framework for hemangiosarcoma were specifically queried. Similar approaches were reported earlier with 2-BE (Laifenfeld et al, 2010) and pregabalin (Criswell et al., 2012a,b) . As shown in Table 9 , fenretinide had the largest number of DEGs, followed by troglitazone then elmiron. All DEGs are listed in Supplementary Table 4.
In the work described here, the focus was on hypotheses related to hypoxia, inflammation, and hemangiosarcoma/angiogenesis/cell proliferation. The primary goal was to assess whether transcriptomics detected evidence of hypoxia, macrophage activation using inflammation pathways as the biomarker, angiogenic growth factor upregulation, and hemangiosarcoma pathway activation in the target organ for HS. The second goal was to assess whether transcriptomics was more sensitive than hypoxyprobe in detecting hypoxia. For macrophage activation, it is tissue specific activation that is most critical. For hypoxia, it can either be tissue specific as in the case of troglitazone or global hypoxia as seen with 2-BE and pregabalin (Criswell et al., 2012) . The results of the CRE provides inferred upstream controllers that explain the DEG response and are referred to as hypotheses, the direction of these hypotheses may not be the same as the directional changes of individual genes. The hypotheses supporting hypoxia were initially identified by (Laifenfeld et al., 2010) and included HIF1a, EPAS1, and "response to hypoxia". Inflammation hypotheses also came Hypoxyprobe immunostaining was observed in the liver of troglitazone-treated mice (B), the femoral bone marrow of elmiron-treated mice (D), and the WATs of fenretinide-treated mice (F), compared with the respective study control mice (A,C,E). All tissues counter stained with hematoxylin. from the same paper (toll-like receptor 4 [TLR4], NF-kb, IL1b, IL6), but were supplemented by others associated with "wellknown" inflammatory mediators such as lipopolysaccharide (LPS), tumor necrosis factor alpha (TNFa), and interferon gamma (INFc). Finally, we identified hypotheses related to "hemangiosarcoma" using the LitMS tool that is part of the CRE. Some of the hemangiosarcoma hypotheses overlapped with those reported for EC proliferation in (Laifenfeld et al., 2010) , such as phosphatase and tensin homolog (PTEN), and numerous processes involved in cell cycle progression such as myc oncogene (Myc) and cyclin D1 (ccnd1). Additional hypotheses were related more specifically to angiogenesis (eg, VEGF, transforming growth factor beta (TGFb), mesenchymal-epithelial transition (MET), Telomerase Reverse Transcriptase [TERT] , and tumor protein 53 [TP53]); importantly, these growth factors also stimulate EC proliferation. A tabular summary of these hypotheses is shown in Table 9 and a complete list of all significant hypotheses is shown in Supplementary Table 5 .
Effects of fenretinide. The original goal of this study was to profile both WAT and epididymis, but only WAT was profiled because the transcriptomic data from the epididymis did not yield any DEGs, likey due to the inability to reproducibly dissect uncontaminated regions of epididymal tissue. As noted earlier, treatment with fenretinide produced the strongest transcriptional response of all 3 compounds, with over 3 thousand DEGs at days 15 and 29. Support for hypoxia was seen at both time points, with an increase in EPAS1 at days 15 and 29, and an increase in HIF1a and "response to hypoxia" also seen at day 29 only. Response to hypoxia was among the most significant hypotheses of the 354 that were identified in the day 29 treatment group. Hypotheses supporting a mixed inflammatory response were seen at day 15, while these same hypotheses were strongly increased at day 29. In fact, the LPS hypothesis was the top ranked of all at day 29, with TNFa nearly equally as strong. When clustered, the top 10 hypotheses from the day 29 group form a network of inflammatory changes as shown by the associated MeSH cloud (Figure 3) . At day 15, there was evidence of VEGFa increase, and by day 29 there were increases in several angiogenic growth factor hypotheses and a concommitent decrease in TGFb. With the hemangiosarcoma-related hypotheses, there were overlapping hypotheses at both time points (PPARG, TERT, MYC, Harvey RAS oncogene [HRAS], TP53, VEGFa), but in some cases the directions were opposite. The hemangiosarcoma hypotheses for both time points cluster into wellconnected networks, and their associated MeSH clouds include terms consistent with relevent pathological process, such as cell transformation and neovascularization (Figure 4) . Effects of troglitazone. Both BAT and liver from mice treated with troglitazone for 15 or 29 days were profiled. There were more DEGs in the liver at both time points than in the BAT, but not as many DEGs compared with WAT from fenretinide-treated mice ( Table 9 ). The strongest hypotheses in the liver and BAT were assocated with the primary pharmacology of the drug, including PPARc (data not shown). The only changes associated with hypoxia were decreased HIF1a and decreased response to hypoxia at day 29 in the liver. For inflammation, there were changes at both time points in the BAT, and only a weak response (increased LPS) at day 29 in the liver. Growth factor changes were not seen in either tissue at day 15. In the BAT at day 29, changes in VEGFa and TGF-b were seen, but in opposite directions as seen with fenretinide. In the BAT, several hypotheses associated with the LtMS tag "hemangiosarcoma" were changing in BAT at days 15 and 29, with only weak changes at both time points in liver.
Effects of elmiron. The transcriptional response in livers of mice treated with elmiron was the weakest of all 3 compounds. On day 15 the most statistically significant change was in 1 hypothesis related to inflammation (TLR7"), and weak changes in the growth factor erythropoietin (EPO) and growth factor receptor MET. On day 29 there were no significant changes related to hypoxia, inflammation, growth factors or hemangiosarcoma. Total cell count -
Arrow indicates direction of change in treated group in relation to vehicle control group (fold change increase or percent decrease). All changes included in the table are statistically significant (p < .05).
DISCUSSION
Although HS are a rare tumor type in humans, they occur with increased frequencies in rodents, particularly mice, and have been an impediment to drug approval . A common MOA appears to exist for the nongenotoxic induction of hemangiosarcoma in mice based on the characterization of responses from mice treated with 2-BE, pregabalin, and troglitazone . Although the specific initiating events may vary by the compound, there is evidence that convergence of these multiple initiating events leads to a dysregulation of angiogenesis and/or erythropoiesis that results from hypoxia or macrophage activation . We have previously shown that pregabalin and 2-BE contain key components of the proposed model for HS induction including dysregulated erythropoiesis/angiogenesis, hypoxia generation, macrophage increases and activation, and EC proliferation (Criswell et al., 2012a,b; Laifenfeld et al., 2010) . In the review by Cohen et al. (2009) , troglitazone data sets had not utilized hypoxyprobe or used the CD-31/BrdU dual cell proliferation methods that had been used with 2-BE and pregablin and therefore it was included in this study along with 2 other biologically diverse drugs with varying potency for HS-induction: fenretinide (high), troglitazone (intermediate), and elmiron (low). The goal was to compare the key elements in the proposed model for nongenotoxic hemangiosarcoma induction in mice with the previous work on 2-BE and pregabalin . The 5 key elements of the MOA include hypoxia (Hypoxyprobe, transcriptomics), macrophage activation (hematology, transcriptomics), growth factors (surrogate was extramedulary hematopoiesis-EMH, transcriptomics), dysregulated angiogenesis/erythropoiesis (hematology, transcriptomics), and EC proliferation (CD31/BrdU dual staining). For transcriptomics, the focus was on whether evidence of hypoxia, macrophage activation using inflammation pathways as the biomarker, angiogenic growth factor upregulation, and hemangiosarcoma pathway activation in the target organ for HS could be detected. The 2 primary goals of this report were to assess the MOA by adding 3 additional compounds to increase the weight of evidence and to assess the robustness of the experimental endpoints (eg, hypoxyprobe versus transcriptomics).
Fenretinide is a synthetic retinoid that has been explored for its effects on obesity and type-2 diabetes through its apoptotic effects on adipocytes (Mody and McIlroy, 2014) . In a 2-year Response to hypoxia", HIF1a", EPAS1"
TNF ",
MET ",TNF ", B6C3F1 mouse carcinogenicity study, fenretinide was found to be a highly potent HS-inducing agent, producing nearly 100% incidence of hemangiosarcoma in male and female mice in the hemolymphoreticular system (ie, bone marrow, liver, lymph node, spleen) ( Table 1, Cromwell and Goldenthal, 2006) . In male mice, HS were also reported in the epididymis and epididymal white fat pads; hence, epididymal WAT and epididymis were included in the study design. Dysregulated erythropoiesis was apparent in fenretinide-treated mice as there was a decrease in reticulocyte response in the face of decreased red blood cell (RBC) counts and hemoglobin levels coupled with a increase in bone marrow macrophage number (6-to 11-fold at days 15, 29, and 92). Consistent with dysregulated erythropoiesis, spleen weights were increased at all time points and extramedullary hyperplasia and EMH were observed at days 29 and 92. These changes were accompanied by splenic hypoxia at days 29 and 92 (Hypoxyprobe). Liver EC proliferation was statistically significant at days 15, 29, and 92 although liver hypoxia was only seen at day 29. On day 92 increased immunostaining for mitochondrial markers porin ( Figure 2 ) and mnSOD (data not shown) in the liver was present indicating a response to mitochondrial injury (Parmar et al., 2011) and oxidative stress (Candas and Li, 2014) , respectively. Interestingly, porin immunostaining intensity was greater with fenretinide treatment than with troglitazone or elmiron suggesting that fenretinide results in greater mitochondria injury response than the other 2 compounds. mnSOD staining intensity was elevated similarly for all 3 treatments indicating that these compounds resulted in increased oxidative stress in the liver (data not shown), a response consistent with that reported with 2-BE (Corthals et al., 2006; Klaunig and Kamendulis, 2005; Park et al., 2002a,b; Siesky et al., 2002) . Fenretinide-treated mice demonstrated a decrease in WAT weight consistent with transdifferentiation of white adipose to brown adipose phenotype as well as an increase total cell proliferation (all time points). Consistent with increased cell proliferation in WAT at day 29 were numerous hypotheses indicative of angiogenic growth factors (ANGPT1 ", fibroblast growth factor 2 (FGF2) " VEGFa" and EPO", and TGFb#) based on analysis of the gene expression data. TGFb is known to inhibit EC proliferation (Fr ater-Schrö der et al., 1986) so the predicted decrease in its expression would be expected to be permissive for proliferation. Evidence for hypoxia in WAT using Hypoxyprobe was seen only at D29, and this was strongly supported by transcriptomics evidence of increased hypoxia. Although there was no histological evidence of inflammation in the WAT, the transcriptomics data provided strong support for an increased inflammatory response at day 29, including a specific reference to "macrophage activation" from the supporting MeSH cloud (Figure 3) . Hence, fenretinide demonstrated all 5 key elements of the proposed MOA for hemangiosarcoma: hypoxia (liver, spleen, WAT) with associated mitochondrial injury and oxidative stress (liver), macrophage activation (bone marrow, transcriptomics in WAT), growth factors (EMH, transcriptomics in WAT), dysregulated erythropoiesis (hematology), and endothelial/total cell proliferation (liver, WAT). The correlation between hypoxia and EC proliferation was strongest for the liver compared with WAT. And finally, the high number of significant hypotheses related to "hemangiosarcoma" that were identified at both days 15 and 29 of fenretinide treatment further demonstrate support for the proposed MOA. Troglitazone is a thiazolidinedione that binds and activates the PPARc resulting in inhibition of hepatic gluconeogenesis and enhancement of insulin activity (Saltiel and Horikoshi, 1995; Saltiel and Olefsky, 1996) . In the 2-year mouse carcinogenicity study, troglitazone produced a 2.7-fold increase in total hemangiosarcoma incidence in male (800 mg/kg) and female (400 mg/kg) mice when compared with the concurrent control groups (27% incidence for all organs, Table 1 ) (Herman et al, 2002) . Hence, the incidence of hemangiosarcoma in troglitazone-treated mice is 3.7-fold less than fenretinidetreated mice. In male mice treated with troglitazone, HS were elevated in the liver, bone marrow, skin/subcutis, and spleen (Herman et al., 2002) . Dysregulated erythropoiesis was apparent in troglitazone-treated mice based on the decrease in reticulocyte counts (14%-29% on days 29 and 92, respectively) in the face of decreased RBC counts (days 15 and 29) and hemoglobin levels coupled with a increase in bone marrow macrophage (4-7-fold, days 15, 29, and 92). In contrast to fenretinide, spleen weights were decreased at day 92 secondary to lymphoid depletion consistent with previous reports of troglitazone's antiinflammatory actions (Ghanim et al., 2001) . There was no evidence of splenic hypoxia at any time point via hypoxyprobe.
Troglitazone has been reported to cause hyperplasia of BAT and this increase in adipocytes could have been a potential source for angiogenic growth factors (Herman et al., 2002 ). In the current study, we also observed transdifferentiation of BAT into a white adipose phenotype in troglitazone-treated mice consistent with PPARc activation (Breider et al., 1999 ). An increase in BAT EC proliferation was observed at days 15 and 92 but without any evidence of hypoxia via hypoxyprobe or transcriptomics. Hepatocellular hypertrophy consistent with enzyme induction (Kim et al., 2008; Wang et al., 2008) was observed at all time points, while hepatic EC proliferation was only increased at day 15 and hypoxia was observed at days 15 and 92. In the liver, at day 29 there was transcriptional evidence for a decrease in hypoxia, something that was also seen in bone marrow following 7 days treatment of mice with 2-BE, another compound that causes hemangiosarcoma (Laifenfeld et al., 2010) . KakiuchiKiyota et al. (2009) reported a 2.95-fold increase in liver EC proliferation in female mice administered 400 mg/kg troglitazone. Increased immunostaining for porin ( Figure 2 ) and mnSOD (data not shown) was also observed in the liver at day 92 supporting mitochondrial injury and oxidative stress responses in this tissue, the latter is consistent with that seen with 2-BE (Corthals et al., 2006; Klaunig and Kamendulis, 2005; Park et al., 2002a,b; Siesky et al., 2002) . Breider et al. (1999) reported a 4-and 1.52-fold increase in BAT EC proliferation after 7 and 14 days, respectively, in female B6C3F1 mice treated with 1200 mg/kg troglitazone. We observed a 2.4-fold increase in BAT EC proliferation at day 15, which is similar to the other 2 groups. In summary, troglitazone demonstrated 4 of the 5 key elements of the proposed MOA for hemangiosarcoma: hypoxia (liver, BAT) with associated mitochondrial injury and oxidative stress (liver), macrophage activation (bone marrow), dysregulated erythropoiesis (hematology), and endothelial/total cell proliferation (liver, BAT). The correlation between hypoxia and EC proliferation was less strong than that observed with fenretinide. Because there was single cell necrosis seen in the liver, one cannot rule out a confounding transcriptional response for the liver only. This caveat was minimized because the transcriptional analysis was focued on confirming previously described changes associated with the MOA observed with other compounds that induce hemangiosarcoma.
Elmiron is used for the chronic treatment of interstitial cystitis, a disorder characterized by bladder pain and urinary urgency in the absence of infection (Anderson and Perry, 2006) . In sub-chronic studies, chronic inflammation and increased incidence of vacuolated histiocytes in multiple tissues including rectum, lymph nodes, liver and spleen were observed (NTP TR 512, 2004) . In the 2-year B6C3F1 mouse carcinogenicity study, elmiron increased hepatic hemangiosarcoma incidence in male (168 and 502 mg/kg, 8% and 18%, respectively) and female (504 mg/kg, 8%) mice compared with the concurrent controls (4% and 0% male and female, respectively) ( Table 1, Abdo et al., 2003) . HS were only evident in mouse liver unlike the findings from the fenretinide and troglitazone carcinogenicity studies that had multiple organs with hemangiosarcoma. The incidence of hemangiosarcoma in elmiron-treated mice is 5.6-fold less than fenretinide-treated mice. Dysregulated erythropoiesis was apparent in elmiron-treated mice as there was a decrease in reticulocyte response in the face of decreased RBC counts and hemoglobin levels coupled with a increase in bone marrow macrophage number (4-, 7-, and 8-fold on days 15, 29, and 92, respectively). The decreases in RBC and hemoglobin were similar in magnitude and consistent with previous reports (Herman et al., 2002; NTP TR 512, 2004) . Consistent with dysregulated erythropoiesis, spleen weight was increased at day 92, EMH was observed at days 29 and 92, and foamy macrophages were observed at day 92. The foamy macrophages have been attributed to an accumulation of neutral and acidic mucins, lipids, and possibly elmiron itself within the lysosomes of macrophages similar to that seen with lysosomal storage disorders and this change is hypothesized to lead to the sustained local production of growth factors (eg, VEGF) which may in turn result in increased EC proliferation (Nyska et al., 2002) . These changes were accompanied by splenic hypoxia at day 92 (Hypoxyprobe). The extramedullary hyperplasia observed in the spleens of elmirontreated mice is most likely a secondary adaptive response to the erythrocyte decreases and the absence of a regenerative bone marrow response seen with these compounds.
As expected, there were no effects on BAT and WAT, except for a mixed cell infiltrate in the WAT. In the liver, a statistically significant increase was found in both relative and absolute proliferating EC cells at day 92 without any evidence of hypoxia at any time point. The mitochondrial markers, porin ( Figure 2 ) and mnSOD (data not shown), had increased immunostaining in the liver at day 92 which was to a lesser degree than that seen for other 2 compounds. In summary, elmiron demonstrated 3 of the 5 key elements of the proposed MOA for hemangiosarcoma: macrophage activation (bone marrow, spleen), dysregulated erythropoiesis (hematology), and EC proliferation (liver). The correlation and magnitude of changes between hypoxia and EC proliferation was less strong than that observed with fenretinide and troglitazone. It is noteworthy that hypoxia in the liver was not detected as this is the organ where hemangiosarcoma was observed. Finally, transcriptional evidence for any of the key steps in the MOA was weak for elmiron.
Of the 5 elements, there was strong evidence for dysregulated erythropoiesis and macrophage activation across all 3 componds. Specifically, a decrease in RBC and a failure to increase reticulocytes coupled with 4 to 11-fold increases in bone marrow macrophages. This pattern of hematological changes in mice might serve as an early biomarker to evaluate EC proliferation in suspected target organs for potential HS formation. Although the mechanism for increases in bone marrow macrophages is unclear, an apoptotic effect on bone marrow adipocytes could potentially stimulate macrophages to remove the extruded nuclei of bone marrow nucleated erythrocytes. The correlation between tissue hypoxia and EC proliferation in the organs where hemangiosarcoma occurred was strongest with fenretinide (liver, WAT-evidence of hypoxia and cell proliferation), intermediate with troglitazone (liver-evidence of hypoxia and cell proliferation, BAT-evidence for cell proliferation but not hypoxia), and weakest for elmiron (liver-evidence for cell proliferation with no evidence of hypoxia). The hypoxyprobe Immunohistochemistry (IHC) probe suffers from a low dynamic response and it was hoped that transcriptomics would improve upon this endpoint. Unfortunately, this was not the case. Although there was evidence of hypoxia using both approaches in WAT at day 29 with fenretinide-treated mice, in livers from troglitazone-treated mice, the increase in hypoxyprobe at day 15 was not accompanied by changes in transcriptomics. Conversely, at day 29 in the troglitazone-treated mice, there was transcriptional evidence of hypoxia in the absence of a signal with hypoxyprobe. The evidence for increased EC growth factors was indirect from the spleen EMH that was only observed with fenretinide and elmiron. Transcriptomics did demonstrate a strong angiogenic growth factor signal with fenretide (day 29, WAT) and weak changes with troglitazone and elmiron. Regarding dysregulated angiogenesis, transcriptomic data demonstrated a strong signal with fenretinide at day 29 in the WAT, and weaker signals at day 29 in liver and BAT with troglitazone.
In summary, this study was conducted with 3 biologically diverse compounds with varying potency for HS-induction: fenretinide (high), troglitazone (intermediate), and elmiron (low). The goal was to compare the key elements in the proposed MOA and increase the weight of evidence for hemangiosacroma formation by usin these 3 drugs with divergent pharmacological properties. The 5 key elements of the MOA are hypoxia in target organs, macrophage activation in the target organ and/or bone marrow, increased angiogenic growth factors, dysregulated angiogenesis/erythropoiesis, and endothial cell proliferation in the organs where hemangiosarcoma is observed . Fenretindine demonstrated all 5 key elements of the proposed MOA for hemangiosarcoma, troglitazone demonstrated 4 of the 5 elements, and, elmiron demonstrated 3 of the 5 elements. The overall transcriptional evidence for the key elements of the proposed MOA were also consistent with the potency of HS induction: fenretinide > troglitazone > elmiron. These data coupled with the previous work with 2-BE and pregabalin increase the weight-of-evidence for this MOA for hemangiosarcoma. Importantly, this time-course demonstrates that the several of the changes in the propsed MOA for HSinduction can be detected in studies up to 3-months in duration, which are routinely used in safety assessment.
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